NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company developing natural killer cell immunotherapies, with programs targeting neurodegenerative diseases including Alzheimer's disease. The company became publicly listed in 2023 through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle that completed its initial public offering in 2021 and was sponsored by Graf Industrial Corp. An 8-K disclosure filed August 30, 2024 reflects the company's continuing SEC reporting obligations in the period following its de-SPAC transaction. NKGN operates within the clinical-stage biotechnology and cell therapy sector. Sign up on SpacDesk for full filings, analytics, and event tracking on NKGN and the broader SPAC universe.